Drug Profile

Salubrin HF - Pherin Pharmaceuticals

Alternative Names: PH80 - Pherin Pharmaceuticals; PH80-HF; PH80-HF NS; Salubrin HF

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pherin Pharmaceuticals
Class Antimigraines
Mechanism of Action Neurotransmitter receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hot flashes
No development reported Migraine

Most Recent Events

28 Jul 2024 No recent reports of development identified for preclinical development in Migraine in USA
02 Feb 2023 Pherin Pharmaceuticals has been acquired by VistaGen Therapeutics
08 Jun 2020 Preclinical trials in Migraine in USA (unspecified route), prior to June 2020 (Pherin Pharmaceuticals pipeline, June 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com